文献速递消化系统肿瘤

FOLFOXIRI联合贝伐珠单抗在仅肝转移的转移性结直肠癌中的疗效:Gruppo Oncologico del Nord Ovest临床研究的汇总分析

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
PubMed 文献 · Eur J Cancer · 2016-12-13

本文汇总三项前瞻性临床试验中接受一线FOLFOXIRI联合贝伐珠单抗治疗的仅肝转移、不可切除转移性结直肠癌患者205例,分析转化切除疗效及高危因素影响。R0/R1切除患者中位无进展生存18.1个月、总生存44.3个月,均显著优于其他患者,且不受临床及分子预后因素影响。

要点

  • 205例仅肝转移患者中74例(36.1%)接受R0或R1切除,17例(8.3%)接受R2切除。
  • R0/R1切除患者中位PFS 18.1个月、OS 44.3个月,显著优于其他患者。
  • 受累肝段<6个及达到RECIST缓解与更高切除机会相关,临床及分子高危因素不影响切除后结局。

核心结论

  • FOLFOXIRI联合贝伐珠单抗在转化治疗中显示疗效,长期结局结果可观,且独立于临床和分子预后因素。

研究设计与样本

  • 对Gruppo Oncologico del Nord Ovest开展的三项前瞻性临床试验(NCT00719797、NCT01163396、NCT02271464)中接受一线FOLFOXIRI联合贝伐珠单抗治疗的不可切除、仅肝转移mCRC患者进行汇总分析。
  • 从541例接受治疗的患者中选取205例(37.9%)仅肝转移患者。

主要发现

  • 肝转移为同时性者占90%,≥4个者占61%,双叶分布者占79%。
  • 最大直径>5 cm者占42%,受累肝段≥6个者占25%。
  • 74例(36.1%)接受R0或R1切除,17例(8.3%)接受R2切除。
  • 受累肝段<6个(p<0.001)及达到RECIST缓解(p=0.019)与更高切除机会相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Secondary resection is a chance of cure for a subgroup of metastatic colorectal cancer (mCRC) patients with unresectable liver-limited disease. Medical treatment has a dual goal: to induce tumour shrinkage and to prevent disease relapse. The aims of the present analysis were to assess the efficacy of FOLFOXIRI plus bevacizumab in this setting, and to investigate whether this regimen could revert the poor prognosis of high-risk patients defined by clinical and molecular factors. We performed a pooled analysis of patients with unresectable and liver-limited mCRC, treated with first-line FOLFOXIRI plus bevacizumab in three prospective clinical trials by Gruppo Oncologico del Nord Ovest. 205 (37.9%) patients with liver-limited disease were selected, out of 541 treated patients. Liver metastases were synchronous, ≥4 and bilobar in 90%, 61%, and 79% of cases, respectively. The largest diameter was >5 cm in 42% of cases, and ≥6 segments were involved in 25%. Seventy-four patients (36.1%) underwent R0 or R1 resection of metastases. R2 resections were performed in 17 cases (8.3%). Having <6 involved segments (p < 0.001) and achieving RECIST response (p = 0.019) were associated with higher chances of resection. R0/R1 resected patients had significantly longer median progression-free survival (PFS) (18.1 versus 10.7 months, HR: 0.48 [0.35-0.66], p < 0.001) and overall survival (OS) (44.3 versus 24.4 months, HR: 0.32 [0.22-0.48], p < 0.001) compared with other patients, both in the univariate and multivariate analyses (PFS p = 0.025; OS p < 0.001). The 5-year PFS and OS rate in R0 resected patients were 12% and 43%, respectively. Neither negative baseline characteristics nor high clinical risk scores or RAS/BRAF mutations were associated with poor post-resection outcomes. In conclusion, FOLFOXIRI plus bevacizumab demonstrates efficacy in the conversion setting with considerable long-term outcome results independent of clinical and molecular prognostic factors (NCT00719797, NCT01163396 and NCT02271464).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Cremolini C, Casagrande M, Loupakis F, et al. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. Eur J Cancer. 2016. PMID: 27986363. doi:10.1016/j.ejca.2016.10.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。